Efficacy of Follitropin-A (Gonal-F) Versus Follitropin-B (Puregon) for Controlled Ovarian Stimulation in Women Undergoing IVF

Hayder Abdulhafedh Kurji, Qutaiba Ahmed Al Khames Aga, Myasar Jasim Mohammed Al- Taie, Yazan A.Bataineh, Mohammed Khudhair Hasan, Ahmed Hazem Abdulkareem, Najlaa Saadi Ismael


The purpose of this study was to compare the efficacy of two recombinant FSH on pregnancy rates in infertile patients.
Material and Methods: between 2015-2017, 387 females intended to have in vitro fertilization (IVF) for infertility treatment (226 patients use Gonal-F and 161 using Puregon.
Results: Serum E2 concentration at hCG time was higher with Follitropin-a treated patients, and a larger number of retrieved oocyte result in a large number of the transferred embryo, and high pregnancy rate than Follitropin-b treated patients.
Conclusions: Gonal-F (Follitropin-a) is associated with a potential stimulatory effect on ovaries. Puregon (Follitropin-b) was associated with a lower clinical pregnancy rate (PR). E2 level 5-7 days after stimulation can be used as an indicator of the success of IVF.


COS, Fertilization, Follitropin-a, Follitropin-b, Gonal-F, IVF, Puregon.

Full Text:


DOI: http://dx.doi.org/10.25258/ijpqa.10.4.21


  • There are currently no refbacks.

Copyright (c) 2019 International Journal of Pharmaceutical Quality Assurance

License URL: https://creativecommons.org/licenses/by-nc-nd/4.0